You are here

Docs Urge Caution as Payments Database Debuts

CMS website draws complaints

A federal database unveiled September 30 details 4.4 million payments from pharmaceutical and medical technology companies to doctors and teaching hospitals, sparking concerns that consumers might misinterpret the information.

The Centers for Medicare & Medicaid Services (CMS) website itemized $3.5 billion worth of payments to 546,000 doctors and 1,360 teaching hospitals made between August 2013 and December 2013. But about 40% of those payments were listed without noting who received them, either because of concerns about whether CMS had the correct recipient information, or because the physicians named hadn’t had enough time to verify the payment information.

The database is the result of a “sunshine act” that was incorporated into the Patient Protection and Affordable Care Act and is intended to intensify scrutiny of the relationships between physicians and the drug and device industries. Consumer advocates have argued that making this information available to the public — on gifts, speaker fees, research grants, meals, travel, and investment interests worth $10 or more — is a vital step in ensuring that doctors don’t have conflicts of interest that affect their research and medical decisions.

Pharmaceutical and medical device companies submitted the information, and CMS was required to give doctors and hospitals 45 days to review and contest any claims.

Another 199,000 records were not published because they detailed ongoing pharmaceutical research or because physicians were still disputing their contents. That information will be updated and published as it becomes ready, according to CMS Deputy Administrator Shantanu Agrawal.

Industry representatives have suggested that the database could distort relationships that are either innocuous or promote valuable research. But those supporting the “sunshine act” say that when making medical decisions, patients have a right to know their doctor’s connections. Research from the Pew Charitable Trusts found that doctors who receive money from the industry will sometimes change their prescription practices based on those interests.

In response to industry concerns, the CMS is working to appropriately contextualize the information included in the database, Agrawal said. In addition to a broader statement explaining what the data may or may not indicate, the site includes information companies may have provided to describe specific payments.

But, given the difficulty some have faced in accessing or navigating the site, it’s still hard to tell how effective some of those explanations have been and how accurate the information is, said Linda Burns, president of the American Society of Hematology.

“We want the data to certainly be transparent and publicly available, but we also understand that it’s only beneficial if the data are complete and accurate,” Burns said. “And I think that’s still yet to be seen.”

Other concerns about the site’s accuracy surfaced earlier this summer. In August, a physician reviewing which payments were attributed to him found incorrect information on the site. After that, the CMS temporarily took the site down to address that information — ultimately leading to the 40% of payments the agency published but did not identify.

That discovery prompted calls from interest groups, such as the American Medical Association, to push back the site’s launch to March 31, 2015. The AMA argued that site inaccuracies could unfairly harm physicians and that technical challenges had left doctors insufficient time to review and challenge the information included.

The CMS intends to unveil a second, more user-friendly site for consumers in October, Agrawal said. Some questioned how accessible the site now is. For instance, a PDF of a dictionary meant to help users navigate the site and understand its terminology spans 51 pages. Others pointed out the lengthy period it takes to download the spreadsheet of payment information.

Source: Kaiser Health News; October 1, 2014.

More Headlines

Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
National Statistics Report Factors In Race, Ethnicity for the First Time
FDA Prioritizing Review of ARB Applications to Help Mitigate Drug Shortage
California Woman Claimed Asbestos in Talc-Based Powder Caused Her Mesothelioma
Synergistic Effects Seen When Combined With Cisplatin in Mice
For Locally Advanced or Metastatic Triple-Negative Type Only